The University of Chicago Header Logo

Connection

Michael R. Bishop to Male

Back to Details
This is a "connection" page, showing publications Michael R. Bishop has written about Male.
Michael R. Bishop
Connection Strength
0.645
Male
  1. Post-autologous transplant maintenance therapies in lymphoma: current state and future directions. Bone Marrow Transplant. 2018 01; 53(1):11-21.
    View in: PubMed
    Score: 0.032
  2. Mature T- and NK-cell non-Hodgkin lymphoma in children and young adolescents. Br J Haematol. 2016 05; 173(4):573-81.
    View in: PubMed
    Score: 0.029
  3. Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Oct; 19(10):1509-13.
    View in: PubMed
    Score: 0.024
  4. Donor lymphocyte infusion: beauty is in the eye of the beholder. Biol Blood Marrow Transplant. 2013 Jun; 19(6):849-50.
    View in: PubMed
    Score: 0.023
  5. Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. Blood. 2013 Apr 11; 121(15):2864-74.
    View in: PubMed
    Score: 0.023
  6. Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients. Bone Marrow Transplant. 2013 Feb; 48(2):269-77.
    View in: PubMed
    Score: 0.022
  7. Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies. J Clin Oncol. 2012 Mar 10; 30(8):830-6.
    View in: PubMed
    Score: 0.022
  8. Monitoring and prevention of relapse after allogeneic hematopoietic cell transplantation for myeloid malignancies. Biol Blood Marrow Transplant. 2012 Jan; 18(1 Suppl):S62-73.
    View in: PubMed
    Score: 0.021
  9. Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma. Cancer. 2010 Feb 15; 116(4):852-62.
    View in: PubMed
    Score: 0.019
  10. Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009 Feb; 15(2):223-30.
    View in: PubMed
    Score: 0.018
  11. Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. J Clin Oncol. 2008 Dec 10; 26(35):5735-41.
    View in: PubMed
    Score: 0.017
  12. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol. 2008 Nov; 19(11):1935-40.
    View in: PubMed
    Score: 0.017
  13. Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant. 2008 Apr; 41(7):635-42.
    View in: PubMed
    Score: 0.016
  14. Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007 Sep; 13(9):1022-30.
    View in: PubMed
    Score: 0.016
  15. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 Nov; 12(11):1150-60.
    View in: PubMed
    Score: 0.015
  16. Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma. Biol Blood Marrow Transplant. 2005 Aug; 11(8):593-9.
    View in: PubMed
    Score: 0.014
  17. Clinical "cytokine storm" as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease. Clin Gastroenterol Hepatol. 2004 Mar; 2(3):237-45.
    View in: PubMed
    Score: 0.012
  18. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. Biol Blood Marrow Transplant. 2003 Mar; 9(3):162-9.
    View in: PubMed
    Score: 0.012
  19. Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease. Bone Marrow Transplant. 2002 Apr; 29(8):709-10.
    View in: PubMed
    Score: 0.011
  20. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood. 2000 Jul 01; 96(1):80-5.
    View in: PubMed
    Score: 0.010
  21. Filgrastim as an alternative to donor leukocyte infusion for relapse after allogeneic stem-cell transplantation. J Clin Oncol. 2000 Jun; 18(11):2269-72.
    View in: PubMed
    Score: 0.010
  22. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant. 2000 Apr; 25(7):717-22.
    View in: PubMed
    Score: 0.009
  23. Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019 11 26; 3(22):3488-3498.
    View in: PubMed
    Score: 0.009
  24. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019 06 25; 3(12):1858-1867.
    View in: PubMed
    Score: 0.009
  25. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
    View in: PubMed
    Score: 0.009
  26. Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2019 03; 60(3):629-638.
    View in: PubMed
    Score: 0.008
  27. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004.
    View in: PubMed
    Score: 0.008
  28. Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome. J Hematother. 1997 Oct; 6(5):441-6.
    View in: PubMed
    Score: 0.008
  29. Allogeneic-blood stem-cell collection following mobilization with low-dose granulocyte colony-stimulating factor. J Clin Oncol. 1997 Apr; 15(4):1601-7.
    View in: PubMed
    Score: 0.008
  30. PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation. J Immunother Cancer. 2017; 5:11.
    View in: PubMed
    Score: 0.008
  31. Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors. Bone Marrow Transplant. 1996 Oct; 18(4):747-53.
    View in: PubMed
    Score: 0.007
  32. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol. 1996 Apr; 14(4):1320-6.
    View in: PubMed
    Score: 0.007
  33. Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant. 2016 06; 22(6):1065-1072.
    View in: PubMed
    Score: 0.007
  34. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016 05; 101(5):634-43.
    View in: PubMed
    Score: 0.007
  35. Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. Leuk Lymphoma. 2016 08; 57(8):1807-13.
    View in: PubMed
    Score: 0.007
  36. Correspondence Regarding the Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues. Biol Blood Marrow Transplant. 2016 Jan; 22(1):183-4.
    View in: PubMed
    Score: 0.007
  37. High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses. Clin Cancer Res. 2015 Oct 01; 21(19):4312-20.
    View in: PubMed
    Score: 0.007
  38. Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2015 Sep; 50(9):1227-34.
    View in: PubMed
    Score: 0.007
  39. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014 Aug; 99(8):1373-9.
    View in: PubMed
    Score: 0.006
  40. Symptom distress predicts long-term health and well-being in allogeneic stem cell transplantation survivors. Biol Blood Marrow Transplant. 2014 Mar; 20(3):387-95.
    View in: PubMed
    Score: 0.006
  41. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013 Dec 12; 122(25):4129-39.
    View in: PubMed
    Score: 0.006
  42. Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia. Exp Hematol. 2013 Sep; 41(9):772-8.
    View in: PubMed
    Score: 0.006
  43. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012 Nov 15; 120(20):4256-62.
    View in: PubMed
    Score: 0.006
  44. Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2012 Dec; 47(12):1552-7.
    View in: PubMed
    Score: 0.005
  45. Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis. Bone Marrow Transplant. 2012 Nov; 47(11):1455-8.
    View in: PubMed
    Score: 0.005
  46. Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas. Biol Blood Marrow Transplant. 2012 May; 18(5):698-707.
    View in: PubMed
    Score: 0.005
  47. A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. Biol Blood Marrow Transplant. 2011 Nov; 17(11):1619-29.
    View in: PubMed
    Score: 0.005
  48. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011 Jun 02; 117(22):5835-49.
    View in: PubMed
    Score: 0.005
  49. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant. 2012 Feb; 47(2):203-11.
    View in: PubMed
    Score: 0.005
  50. Development of severe sclerotic chronic GVHD during treatment with dasatinib. Bone Marrow Transplant. 2010 Sep; 45(9):1469-70.
    View in: PubMed
    Score: 0.005
  51. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood. 2008 Sep 01; 112(5):2092-100.
    View in: PubMed
    Score: 0.004
  52. Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels. Biol Blood Marrow Transplant. 2008 Mar; 14(3):290-300.
    View in: PubMed
    Score: 0.004
  53. Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation. Exp Hematol. 2007 Feb; 35(2):184-92.
    View in: PubMed
    Score: 0.004
  54. Health-related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006 Jul; 38(2):101-9.
    View in: PubMed
    Score: 0.004
  55. Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2006 Feb; 12(2):204-16.
    View in: PubMed
    Score: 0.004
  56. Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis. Biol Blood Marrow Transplant. 2006 Jan; 12(1 Suppl 2):22-30.
    View in: PubMed
    Score: 0.004
  57. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. J Clin Oncol. 2005 Aug 20; 23(24):5788-94.
    View in: PubMed
    Score: 0.003
  58. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. Am J Hematol. 2005 Apr; 78(4):265-74.
    View in: PubMed
    Score: 0.003
  59. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transplant. 2004 May; 33(10):1031-5.
    View in: PubMed
    Score: 0.003
  60. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia. 2003 Mar; 17(3):499-514.
    View in: PubMed
    Score: 0.003
  61. Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study. Cytotherapy. 2003; 5(6):542-52.
    View in: PubMed
    Score: 0.003
  62. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biol Blood Marrow Transplant. 2002; 8(4):213-20.
    View in: PubMed
    Score: 0.003
  63. Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation. Bone Marrow Transplant. 2000 Sep; 26(6):663-6.
    View in: PubMed
    Score: 0.002
  64. Evidence of enhanced iron excretion during systemic phosphorothioate oligodeoxynucleotide treatment. J Toxicol Clin Toxicol. 2000; 38(4):383-7.
    View in: PubMed
    Score: 0.002
  65. Gastroparesis as a cause of nausea and vomiting after high-dose chemotherapy and haemopoietic stem-cell transplantation. Lancet. 1998 Dec 19-26; 352(9145):1985.
    View in: PubMed
    Score: 0.002
  66. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 1998 Sep 01; 92(5):1832-6.
    View in: PubMed
    Score: 0.002
  67. High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Ann Oncol. 1998 Sep; 9(9):1023-6.
    View in: PubMed
    Score: 0.002
  68. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. J Clin Oncol. 1997 Apr; 15(4):1608-16.
    View in: PubMed
    Score: 0.002
  69. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol. 1997 Feb; 15(2):445-50.
    View in: PubMed
    Score: 0.002
  70. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies. Bone Marrow Transplant. 1996 Jun; 17(6):951-6.
    View in: PubMed
    Score: 0.002
  71. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. Ann Oncol. 1996 Feb; 7(2):151-6.
    View in: PubMed
    Score: 0.002
  72. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis. Exp Hematol. 1995 Dec; 23(14):1503-8.
    View in: PubMed
    Score: 0.002
  73. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 1994 Dec; 12(12):2527-34.
    View in: PubMed
    Score: 0.002
  74. Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. Antisense Res Dev. 1993; 3(4):383-90.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.